Loading...

IMNM IMMUNOME INC Company Mergers 8-K Filing

MMNM

MNM

IMMUNOME INC

(IMNM)

2024 8-K

Show Summary

Summary

Increase in common stock re...

Financial Results

Public Offering

CFO Relocation Package

Q3 Financial Results

Asset Acquisition

Equity Award Plan

Q2 Financial Results

Financial Results and Busin...

Resignation and Appointment

Appointment of Sandra Swain...

Financial Results Announcement

Asset Acquisition

Public Offering

Asset Purchase Agreement

Promotion and Compensatory ...

Presentation Update

License Agreement and Stock...

Appointment of Director and...

Departure of Directors or C...

Acquisition Agreement

Amendment to Merger Filing

Presentation Update

Financial Results Announcement

Appointment of Director

Merger and Amendments

Financial Results Announcement

Investor Meetings

Merger Agreement

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Collaboration Agreement wit...

Agreement with Whitehead In...

External Links:

Immunome, Inc. has acquired certain intellectual property assets from Zentalis Pharmaceuticals for 1,805,502 shares of common stock and a $5 million milestone payment, while terminating a previous license agreement.

AI Assistant

IMMUNOME INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.